Abstract:Heparanase has been identified as a universal tumor-associated antigen, but heparanase epitope peptides are difficult to recognize. Therefore, it is necessary to explore novel strategies to ensure efficient delivery to antigen-presenting cells. Here, we established a novel immunotherapy model targeting antigens to dendritic cell (DC) receptors using a combination of heparanase CD4 + and CD8 + T-cell epitope peptides to achieve an efficient cytotoxic T-cell response, which was associated with strong activation of DCs. First, pegylated poly(lactic-coglycolic acid) (PLGA) nanoparticles (NPs) were used to encapsulate a combined heparanase CD4 + and CD8 + T-cell epitope alone or in combination with Toll-like receptor 3 and 7 ligands as a model antigen to enhance immunogenicity. The ligands were then targeted to DC cell-surface molecules using a DEC-205 antibody. The binding and internalization of these PLGA NPs and the activation of DCs, the T-cell response and the tumor-killing effect were assessed. The results showed that PLGA NPs encapsulating epitope peptides (mHpa399 + mHpa519) could be targeted to and internalized by DCs more efficiently, stimulating higher levels of IL-12 production, T-cell proliferation and IFN-γ production by T cells in vitro. Moreover, vaccination with DEC-205-targeted PLGA NPs encapsulating combined epitope peptides exhibited higher tumor-killing efficacy both in vitro and in vivo. In conclusion, delivery of PLGA NP vaccines targeting DEC-205 based on heparanase CD4 + and CD8 + T-cell epitopes are suitable immunogens for antitumor immunotherapy and have promising potential for clinical applications.

Controlling Nanoparticle Uptake in Innate Immune Cells with Heparosan Polysaccharides

Nanoparticle Surface Engineering with Heparosan Polysaccharide Reduces Serum Protein Adsorption and Enhances Cellular Uptake

Designing selenium polysaccharides-based nanoparticles to improve immune activity of Hericium erinaceus

Reducing Non-Specific Binding and Uptake of Nanoparticles and Improving Cell Targeting with an Antifouling PEO-b-PγMPS Copolymer Coating

Nanopore-regulated in situ polymerization for synthesis of homogeneous heparan sulfate with low dispersity

Development of Sialic Acid-coated Nanoparticles for Targeting Cancer and Efficient Evasion of the Immune System

In vitro and in vivo evaluation of DC-targeting PLGA nanoparticles encapsulating heparanase CD4+ and CD8+ T-cell epitopes for cancer immunotherapy

Overcoming Intestinal Barriers by Heparanase-Responsive Charge-Converting Nanocarriers

Synthesis of Novel Glycolipid Mimetics of Heparan Sulfate and Their Application in Colorectal Cancer Treatment in a Mouse Model

Multi-walled carbon nanotube polysaccharide modified Hericium erinaceus polysaccharide as an adjuvant to extend immune responses

Design Principle of Heparanase Inhibitors: A Combined In Vitro and In Silico Study

Poly(ethylene glycol) Cross-Linked Antibody Nanoparticles for Tunable Biointeractions

Harnessing the potential of de-sulfated heparin for targeted drug delivery: A three-component approach exemplified by conjugation with galactose and paclitaxel

Advanced Nanocarriers Based on Heparin and Its Derivatives for Cancer Management.

Epitope mapping by a Wnt-blocking antibody: evidence of the Wnt binding domain in heparan sulfate

Hyaluronan-modified nanoparticles for tumor-targeting

Harnessing the Power of Sugar-Based Nanoparticles: A Drug-Free Approach to Enhance Immune Checkpoint Inhibition against Glioblastoma and Pancreatic Cancer

Chemoenzymatic synthesis of sulfur-linked sugar polymers as heparanase inhibitors

Selective Decoating-Induced Activation of Supramolecularly Coated Toxic Nanoparticles for Multiple Applications

Optimization of Hericium erinaceus polysaccharide-loaded Poly (lactic-co-glycolicacid) nanoparticles by RSM and its absorption in Caco-2 cell monolayers

In Situ Heparan Sulfate-Induced Peptide Self-Assembly to Overcome the Cell Surface Glycocalyx Barrier for Cancer Treatment